Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: Informing decision-making for universal access to quality tuberculosis diagnosis in India: an economic-epidemiological model

Fig. 5

Cost-effectiveness acceptability curves comparing decentralized versus centralized Xpert testing for tuberculosis (TB) in a representative simulated Indian population. The x-axis shows the cost per disability-adjusted life year (DALY) averted via decentralized Xpert compared to centralized testing, and the y-axis shows the proportion of stochastic simulations falling below each corresponding cost-effectiveness threshold. Dotted vertical lines represent alternative thresholds for evaluating cost-effectiveness. For each threshold, the cost-effectiveness values are computed for the four unit-cost comparisons when centralized specimen transport is utilized at no vs. 95% cost sharing and mean peripheral testing volume ranges from 0.3 to 3 per day in the decentralized scenario

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us